Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth. The majority of affected individuals have been reported in the Afrikaner population of South Africa, where a high incidence of the disorder occurs as a result of a founder effect. Homozygosity mapping in Afrikaner families along with analysis of historical recombinants localized sclerosteosis to an interval of approximately 2 cM between the loci D17S1787 and D17S930 on chromosome 17q12-q21. Here we report two independent mutations in a novel gene, termed "SOST." Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene. The SOST gene encodes a protein that shares similarity with a class of cystine knot-containing factors including dan, cerberus, gremlin, prdc, and caronte. The specific and progressive effect on bone formation observed in individuals affected with sclerosteosis, along with the data presented in this study, together suggest that the SOST gene encodes an important new regulator of bone homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in genes that have highly enriched expression in osteocytes cause rare bone and mineral disorders.”
From Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease (2021) · cites this paper as [17]
Citations
Cites
Bone: Formation by Autoinduction
Urist, M. R. (1965) · Science · doi:10.1126/science.150.3698.893 · Cited by 5,546 · cited 1×
“Although this family of morpho-gens was originally identified on the basis of bone-in-ducing activity (Urist 1965), a number of these factors have been shown to be critical for very early stages of embryogenesis and fetal development.”
Prediction of complete gene structures in human genomic DNA
Burge, C., & Karlin, S. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0951 · Cited by 4,228 · cited 8×
“The novel variant gene (designated “P50gsc3”) predicted by GENSCAN was located between markers D17S951 and D17S1860 (fig.”
InfluentialA comprehensive genetic map of the human genome based on 5,264 microsatellites
Dib, C., Fauré, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Kazan, J., Seboun, E., et al. (1996) · Nature · doi:10.1038/380152a0 · Cited by 2,928 · cited 3×
“D17S1793, D17S1789, D17S951, and D17S1860 within the critical region bounded by D17S1787 and D17S930, an interval of ∼ 2 cM (Dib et al. 1996) on the cytogenetic border between the chromosomal bands 17q12–q21.”
Bone morphogenetic proteins: multifunctional regulators of vertebrate development.
Hogan, B. L. (1996) · Genes & Development · doi:10.1101/gad.10.13.1580 · Cited by 1,962
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Currently there is no effective treatment for the restoration of normal bone mass in individuals with pathologically low skeletal density, and there is a large unmet need for therapy that can increase bone deposition in osteoporosis (Rodan and Martin 2000).”
BackgroundEasy calculations of lod scores and genetic risks on small computers.
Lathrop, M. G., & Lalouel, J.-M. (1984) · Europe PMC (PubMed Central) · Cited by 1,526
Faster sequential genetic linkage computations.
Cottingham, R. W., Idury, R. M., & Schäffer, A. A. (1993) · Europe PMC (PubMed Central) · Cited by 1,364
Nonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992 · cited 1×
“The relatively low levels of mutant transcripts observed could be the result of nonsense-mediated mRNA decay, as the inclusion of intronic sequence introduced an in-frame nonsense codon (Frischmeyer and Dietz 1999; Hentze and Kulozik 1999).”
BackgroundHomozygosity Mapping: A Way to Map Human Recessive Traits with the DNA of Inbred Children
Lander, E. S., & Botstein, D. (1987) · Science · doi:10.1126/science.2884728 · Cited by 875
FORMATION AND FUNCTION OF SPEMANN'S ORGANIZER
Harland, R., & Gerhart, J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.611 · Cited by 839 · cited 1×
“In addition, the requirement for the coordinated expression of negative regulators of BMP activity, such as noggin and chordin, as well as members of the dan family, has been well described (Harland and Gerhart 1997; Sasai and De Robertis 1997; Hsu et al. 1998).”
Background
Research works printed but not linked: 3
- Gardner J (1999) Profound childhood deafness in South Africa: a clinical and molecular genetic approach. Ph.D. thesis, University of Cape Town, Cape Town
- Hausen, 1967, Sklerosteose, Vol. 6, 351
- Peitruschka, 1958, Weitere Mitteilungen über die Marmorknochenkrankheit (Albers-Schonbergsche Krankheit) nebst Bemerkungen zur Differentialdiagnose, Klin Monatbl, 132, 509
Cited by
Items 801–900 of 1,000
Vía Wnt y esclerostina como nuevas dianas para la evaluación y el tratamiento de la osteoporosis
Alonso, G., García‐Martin, A., & Muñoz‐Torres, M. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.03.006 · Cited by 2
Craniodiaphyseal dysplasia: A Rare And Successful Bone-Anchored Hearing Aid Implantation
da Costa, J. C., Santos, M., Coutinho, M. B., Soares, T. C., & Sousa, C. A. E. (2019) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2019.05.022 · Cited by 2
Provot, S., Schipani, E., Wu, J. Y., & Kronenberg, H. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00003-4 · Cited by 3
Sclerostin immunohistochemical staining in surgically treated giant cell tumor of bone
Kelly, S. P., Ramkumar, D. B., Peacock, Z. S., Newman, E. T., Venrick, C. B., Lozano‐Calderón, S. A., Raskin, K. A., Chebib, I. A., & Schwab, J. H. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.26903 · Cited by 2
GNAS gene mutations affecting XLαs and bone health: A long neglected relationship
Xie, Y., Chen, X., Xie, Y., & Yu, X. (2023) · Clinical Genetics · doi:10.1111/cge.14378 · Cited by 2
Serum sclerostin is associated with recurrent kidney stone formation independent of hypercalciuria
Rodríguez, D., Gurevich, E., Jouabadi, S. M., Arroyo, E. M. P., Ritter, A., Younes, S. E., Wagner, C. A., Silva, P. H. I., Seeger, H., & Mohebbi, N. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad256 · Cited by 2
New Emerging Aspect of Herbal Extracts for the Treatment of Osteoporosis: Overview
Kumari, P., Shirumalla, R. K., Bhalla, V., & Alam, M. S. (2024) · Current Rheumatology Reviews · doi:10.2174/0115733971273691231121131455 · Cited by 2
Exome sequencing identified mutations in the WNT1 and COL1A2 genes in osteogenesis imperfecta cases
Mehta, P., Vishvkarma, R., Gupta, S. K., Chattopadhyay, N., & Rajender, S. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09326-7 · Cited by 2
“Since the identification of WNT1 mutations in OI, the involvement of WNT1 in bone formation and maintenance has been extensively studied [ 11–14 , 24 ].”
Katchkovsky, S., Meiri, R., Lacham‐Hartman, S., Orenstein, Y., Levaot, N., & Papo, N. (2024) · FEBS Letters · doi:10.1002/1873-3468.15033 · Cited by 4
Sarusie, M. V., Rönnbäck, C., Jespersgaard, C., Baungaard, S., Ali, Y., Kessel, L., Christensen, S. T., Brøndum‐Nielsen, K., Møllgård, K., Rosenberg, T., et al. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae134 · Cited by 2
Genetic Influences and Targeted Treatments in Osteoporosis: A Systematic Review
Zurel, F., Bux, H., Diveli, A., & Rashid, Z. (2025) · Cureus · doi:10.7759/cureus.87436 · Cited by 8
“LRP5 knockout in mice decreased bone mass, as seen in osteoporosis [33,37].”
Serum Sclerostin as Biomarker in Osteogenesis Imperfecta
Kocijan, R., Dinu, S., & Muschitz, C. (2015) · Exposure and Health · doi:10.1007/978-94-007-7745-3_5-1 · Cited by 2
Perdu, B., Mortier, G. R., Vanhoenacker, F. M. H. M., & Hul, W. V. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-382040-2.10020-6 · Cited by 3
Control of bone mass by sclerostin: Inhibiting BMP- and WNT-induced bone formation
de Gorter, D. J. J., Krause, C., ten Dijke, P., Löwik, C. W. G. M., & van Bezooijen, R. L. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8552-1_14 · Cited by 3
Vitamin D and Wnt/β-Catenin Signaling
González‐Sancho, J. M., Larriba, M. J., & Múñoz, A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-381978-9.10013-7 · Cited by 3
The non-canonical Wnt5a/Ror2 signaling pathway in bone metabolism
Sonomoto, K., Yamaoka, K., & Tanaka, Y. (2014) · Inflammation and Regeneration · doi:10.2492/inflammregen.34.103 · Cited by 2
Boudin, E., & Hul, W. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804182-6.00029-0 · Cited by 2
Vitamin D Activities in Osteocytes
Anderson, P., Atkins, G. J., Morris, H. A., & Findlay, D. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809965-0.00019-7 · Cited by 2
How Basic Science Discoveries Have Shaped the Treatment of Bone and Mineral Disorders
Langdahl, B. L., & Ralston, S. H. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3316 · Cited by 2
“Linkage analysis of families with sclerosteosis and the related syndrome of Van Buchem disease localized both disease genes to chromosome 17q12–q21((64)) and subsequent positional cloning identified loss-of-function mutations affecting the coding region of SOST (the gene that encodes sclerostin) as the cause of sclero…”
BackgroundRecent advances in models for screening potential osteoporosis drugs
Merlotti, D., Materozzi, M., Picchioni, T., Bianciardi, S., Alessandri, M., Nuti, R., & Gennari, L. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1480609 · Cited by 2
Devecı, D. (2018) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2018.06.001429 · Cited by 2
“The gene that encodes sclerostin or SOST, is mutated in the disease sclerosteosis, which is typically presented with increased BMD throughout life [6].”
BackgroundBellido, T., Pajevic, P. D., & Bonewald, L. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804182-6.00014-9 · Cited by 5
Pharmacologic basis of sclerostin inhibition
Ke, H. Z., Roberts, S. J., & Holdsworth, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00074-9 · Cited by 2
Perdu, B., & Hul, W. V. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387829-8.00023-8 · Cited by 3
Parviainen, R., Skarp, S., Korhonen, L., Serlo, W. S., Männikkö, M., & Sinikumpu, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8885 · Cited by 2
Wang, A., Karunasinghe, N., Plank, L. D., Zhu, S., Osborne, S., Brown, C., Bishop, K. S., Schwass, T., Tijono, S., Holmes, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94090-y · Cited by 2
Rozental, T. D., Merchan, N., Jóhannesdóttir, F., Lechtig, A., Earp, B. E., Harper, C. M., & Bouxsein, M. (2021) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.21.00540 · Cited by 2
Wnt Signaling Associated Human Diseases
Lu, Y., Han, J., Ren, X., & Wang, Y. (2018) · doi:10.19080/ntab.2018.03.555607 · Cited by 3
Ralston, S. H. (2001) · BoneKEy-Osteovision · doi:10.1138/2001022 · Cited by 2
[Is today's man really less fertile?].
Marmor, D., Izard, V., Schahmanèche, D. D., Benoît, G., & Jardin, A. (1998) · PubMed · Cited by 5
Pathophysiology of The Chronic Kidney Disease–Mineral Bone Disorder
Hruska, K. A., Sugatani, T., & Williams, M. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11271-1 · Cited by 2
Mackem, S. (2005) · Wiley eBooks · doi:10.1002/9783527619689.ch15 · Cited by 2
Mechanical Properties of Bone Due to SOST Expression: A 3-Point Bending Assessment of Murine Femurs
Peterson, K. J. (2012) · DigitalCommons - CalPoly (California State Polytechnic University) · doi:10.15368/theses.2012.49 · Cited by 2
“3 Sclerosteosis Sclerosteosis is a cranio-tubular hypersteosis that is phenotypically indistinguishable from Van Buchem disease except that it is more severe and occasionally displays syndactyly of the digits, a trait absent in Van Buchem disease [34-37].”
BackgroundModified enzymatic collagen digestion-mediated isolation of osteocytes
Xu, W., DAI, G., LYU, Y., ZHANG, Y., & Tu, X. (2021) · Biocell · doi:10.32604/biocell.2022.017505 · Cited by 1
“This indicated that, different from the previously described osteogenic mechanisms of decreasing sclerostin (Balemans et al., 2002; Brunkow et al., 2001; Heino et al., 2002; Loots et al., 2005), osteocytes, as the terminal cells of bone development, can regulate bone metabolism, regulate the…”
BackgroundAnti-sclerostin antibody – A potential therapeutic target for periodontal bone regeneration
Reghunath, S., Ramesh, R., Nafeesa, R. B., Visalakshy, D. P., Kannappillil, B. P., & Gopalakrishnan, A. (2024) · Journal of Oral Research and Review · doi:10.4103/jorr.jorr_68_23 · Cited by 2
Lee, H. K., Notario, G. R., Won, S. Y., Kim, J. H., Lee, S. M., Kim, H. S., & Cho, S. (2025) · Bone Reports · doi:10.1016/j.bonr.2025.101829 · Cited by 1
“Further, patients with sclerosteosis, which is caused by a rare loss-of-function mutation in the SOST gene, exhibit increased bone mass and elevated BMD (Brunkow et al., 2001; Balemans et al., 2001).”
Novel Loss of Function Variant in SOST From Chinese Family Results in Sclerosteosis 1
Guo, Y., Wu, X., Jin, Y., Gu, Y., Lou, Y., Miao, P., Wang, Y., Zhang, B., Lin, X., Zhang, C., et al. (2025) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.70109 · Cited by 1
Changes in the craniofacial morphology in sclerostin knockout mice
Ikeda, K., Kaku, M., Fan-Yi, C., Shukunami, C., & Tanimoto, K. (2025) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2025.106492 · Cited by 1
Current outlook on the use of monoclonal antibody therapies for osteoporosis
Almohaya, M. S., Almehthel, M. S., & Kendler, D. L. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2641051 · Cited by 1
Serum Sclerostin as Biomarker in Osteogenesis Imperfecta
Kocijan, R., Dinu, S., & Muschitz, C. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7693-7_5 · Cited by 1
Colbert, R. A. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543555.028 · Cited by 1
Contemporary Approaches for Identifying Rare Bone Disease Causing Genes
Farber, C. R., & Clemens, T. L. (2013) · Bone Research · doi:10.4248/br201304001 · Cited by 1
The Variety of Osteocyte Function
O’Brien, C. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800571-2.00006-2 · Cited by 1
Osteoporosis, Mineral Metabolism and Arthritis
Elmesiry, A. M. (2016) · Journal of Osteoporosis and Physical Activity · doi:10.4172/2329-9509.1000165 · Cited by 1
“RANKL has been shown to both mediate osteoclastogenesis and activate mature osteoclasts, whereas OPG negatively regulates RANKL binding to RANK and reduces the half-life of membranous RANKL, therefore inhibiting bone resorption induced by osteoclasts [50].”
BackgroundA true mentor and pioneer in medical genetics
Hayden, M. R. (2016) · South African Medical Journal · doi:10.7196/samj.2016.v106i6.11022 · Cited by 1
Genomics, New Drug Development, and Precision Medicines
McHale, D., & Penny, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-420196-5.00019-8 · Cited by 1
Disorders of Mineral and Bone Metabolism in Chronic Kidney Disease
Hruska, K. A., Seifert, M. E., & Surendran, K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00027-5 · Cited by 2
Newey, P. J., Whyte, M. P., & Thakker, R. V. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch42 · Cited by 2
Pathophysiology of Osteoporosis
Ferrari, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-26757-9_1 · Cited by 2
Wnt signaling and bone cell activity
Williams, B. O., & Johnson, M. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00008-7 · Cited by 1
Kovács, C. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00027-4 · Cited by 2
Osteoporose bei Nierenerkrankung
Cejka, D. (2020) · Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen · doi:10.1007/s41970-020-00108-8 · Cited by 1
[Progress in the regulation of bone remodeling at the cellular level].
Hu, Y., Wang, L., Jiang, L., Xu, H., & Zhu, S. (2017) · PubMed Central · doi:10.7507/1001-5515.201606011 · Cited by 2
Hamaya, E. (2020) · Folia Pharmacologica Japonica · doi:10.1254/fpj.20007 · Cited by 1
Genetische Analysen in der Osteologie
Rötzer, K., & Uyanik, G. (2020) · Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen · doi:10.1007/s41970-020-00126-6 · Cited by 1
Conformational Dynamics of Sclerostin-LRP6 Complex Analyzed by HDX-MS
Jeong, Y., Kim, J., Choi, H., & Chung, K. Y. (2021) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.234 · Cited by 1
“SOST is a secreted glycoprotein, and its loss-of-function mutation was first identified in sclerosteosis (Balemans et al ., 2001; Brunkow et al ., 2001).”
Perry, K. W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818036-5.00013-6 · Cited by 1
Effect of type 2 diabetes on bone cell behavior
Vaidya, R., Church, A. E., & Karim, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821070-3.00001-5 · Cited by 4
"Sclerostin in Oral Tissues: Distribution, Biological Functions and Potential Therapeutic Role"
Han, X. (2020) · Open Access Journal of Biomedical Science · doi:10.38125/oajbs.000228 · Cited by 1
“Sclerostin is a 190 amino acid secreted glycoprotein with a molecular mass of 24kDa and is transcribed from the Sost gene located on chromosome 17q12-21 [1-3].”
BackgroundLauterlein, J.-J., Gossiel, F., Weigl, M., Eastell, R., Hackl, M., Hermann, A. P., Bollerslev, J., & Frost, M. (2021) · JBMR Plus · doi:10.1002/jbm4.10534 · Cited by 1
Cellular and Molecular Biology in Bone Remodeling
DeNapoli, R. C., Buettmann, E. G., & Donahue, H. J. (2021) · Springer eBooks · doi:10.1007/978-981-16-5613-2_1 · Cited by 1
Osteocytes and Bone Regeneration
Atkins, G. J., Prideaux, M., & Findlay, D. M. (2014) · Mechanical engineering series · doi:10.1007/978-3-319-13266-2_3 · Cited by 1
Bone Health in Chronic Kidney Disease
Lu, C., Wu, C., Hou, Y., Zheng, C., & Lu, K. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_30 · Cited by 1
Bone Health: Basic and Applied Bone Biology
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_1 · Cited by 1
Romosozumab: Optimizing the Anabolic Window
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_23 · Cited by 1
Martínez‐Gil, N., Ovejero, D., García‐Giralt, N., Bruque, C. D., Mellibovsky, L., Nogués, X., Rabionet, R., Grinberg, D., & Balcells, S. (2022) · JBMR Plus · doi:10.1002/jbm4.10602 · Cited by 1
Pharmacological Treatment of Osteoporosis
Malouf, J., Magallares, B., & Güerri‐Fernández, R. (2015) · InTech eBooks · doi:10.5772/59469 · Cited by 2
Mundy, G. R., Oyajobi, B. O., Gutierrez, G., Sterling, J. A. R., Padalecki, S. S., Elefteriou, F., & Zhao, M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375098-3.50019-6 · Cited by 1
Bono, F., Rapisarda, L., Bombardieri, C., Gagliardi, M., Procopio, R., Demonte, G., Tosto, F., Bruno, P. A., Gambardella, A., & Annesi, G. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06541-7 · Cited by 1
“Sclerostin deficiency produces generalized skeletal growth [2].”
BackgroundAtiyah, A. G., Hasan, M., & Owain, M. S. (2024) · Egyptian Journal of Veterinary Science · doi:10.21608/ejvs.2024.253317.1700 · Cited by 1
“Additionally, the favorable bone growth was in a macropore powder with porous size greater than 100 microns [21].”
BackgroundBone Remodeling – Clinical Evaluation
Nuti, R. (2023) · Endocrinology · doi:10.1007/978-3-030-19632-5_6-1 · Cited by 1
Song, F., Marmo, T., Song, C., Liao, X., & Long, F. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae122 · Cited by 1
“12,13 16 Interestingly, studies of the Lrp5-null mice also uncovered defects in glucose and cholesterol metabolism besides the expected osteopenia.”
BackgroundEmerging roles of osteocytes in the regulation of bone and skeletal muscle mass
Moin, M. R., Das, S., & Sanyal, S. (2024) · Journal of Molecular Endocrinology · doi:10.1530/jme-24-0033 · Cited by 1
In silico identification of sclerostin inhibitors
Şımşek, Y., Baran, S. S., Ergünol, E., Uludamar, A., Dinçel, A. S., & Erkoç, Ş. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11298-0 · Cited by 1
Translational Medical Research
Olsen, B. R., Amiry-Moghaddam, M. R., & Ottersen, O. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-799943-2.00007-0 · Cited by 1
Tseng, H. (2015) · The University of Queensland · doi:10.14264/uql.2015.886 · Cited by 1
“Sclerostin defects are associated with high bone mass diseases, sclerosteosis and Van Buchem disease [99].”
BackgroundNovel therapeutic targets in osteoporosis
Tobias, J. H., Flanagan, A. M., & Scutt, A. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.1.41 · Cited by 1
Tomatsu, E., Shibata, M., Yoshino, Y., Sekiguchi-Ueda, S., Kakita, A., Takayanagi, T., Makino, M., Hayakawa, N., & Suzuki, A. (2018) · Institutional Repositories DataBase (IRDB) · doi:10.20407/fmj.4.1_1 · Cited by 1
LRPs in Bone Homeostasis and Disease
Wan, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11178-x · Cited by 1
Long, F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11172-9 · Cited by 1
Effects of continuous and intermittent hypergravity on skeleton
Gnyubkin, V. (2015) · theses.fr (ABES) · doi:10.70675/2e978c63z66ebz4a68zb083za6c62d439b14 · Cited by 1
“Sclerostin is a protein selectively produced by osteocytes, product of SOST gene, which negatively regulates bone formation and loss of it causes high bone mass disorders [31,32].”
BackgroundWnt signaling and metaphyseal bone healing
Agholme, F. (2011) · DiVA (Digitala Vetenskapliga Arkivet) · Cited by 1
Diseases of Excess Bone Formation
McLean, W., & Olsen, B. R. (2004) · Springer eBooks · doi:10.1007/978-1-4471-3777-1_7
Pharmacological Treatment of Osteoporosis
Malouf, J., & Güerri‐Fernández, R. (2012) · InTech eBooks · doi:10.5772/30552
Antibodies in Phase III Studies for Immunological Disorders
Ward, P., & Bodmer, M. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch29
New Aspect of Bone Morphogenetic Protein Signaling and Its Relationship with Wnt Signaling in Bone
Kamiya, N. (2012) · InTech eBooks · doi:10.5772/35458
Dysregulation of Wnt Signaling in Breast Cancer
Taj, D., & Li, Y. (2011) · InTech eBooks · doi:10.5772/21696 · Cited by 1
“2, contribute to the pathology of this disease (Balemans et al., 2001; Brunkow et al., 2001).”
BackgroundExploiting knowledge of mesenchymal stromal cells in vivo for bone disease therapy development
Cuthbert, R. (2014) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Characterization of an associated protein kinase of the BMP type II receptor
Schwappacher, R. (2008) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-16660
Clinical Correlate: Van Buchem Disease
Prins, H., Bronckers, A. L. J. J., & Klein‐Nulend, J. (2012) · Wiley eBooks · doi:10.1002/9781118704868.ch9
Vidal, C., & Xuereb‐Anastasi, A. (2011) · InTech eBooks · doi:10.5772/18914
“, 2001) and sclerostin (SOST) genes (Brunkow et al., 2001).”
BackgroundTHE FUNCTION OF NR3B AND NR4A ORPHAN NUCLEAR RECEPTORS IN OSTEOBLASTS
Rajalin, A.-M. (2011) · Helda - University of Helsinki Institutional Repository
Estudio genético de dos fenotipos óseos: osteocondromatosis múltiple y alta masa ósea
Pérez-Caballero, P. S. (2013) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Gut-derived Serotonin and Bone Formation
Ducy, P. F. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-415784-2.00007-5
TGF-β and Genetic Skeletal Diseases
Ikegawa, S., Nakashima, M., & Matsumoto, N. (2013) · Springer eBooks · doi:10.1007/978-4-431-54409-8_16
Osteosklerosen, Hyperostosen und Osteogenesis imperfecta
Kasperk, C. H. (2010) · Elsevier eBooks · doi:10.1016/b978-3-437-24680-7.10042-x
Deyle, D. R., & Westendorf, J. J. (2013) · IBMS BoneKEy · doi:10.1038/bonekey.2013.177
Bejarano, N. S., Jaramillo, L., Duque, M. A. Q., Peñaranda-Parada, E. A., Quintana, G., Federico Rondón, H., Restrepo, J. F., & Gamarra, A. I. (2011) · Revista Colombiana de Reumatología · doi:10.1016/s0121-8123(11)70056-1
Extracellular Modulators Regulate Bone Morphogenic Proteins in Skeletal Tissue
Nifuji, A., Ideno, H., Takanabe, R., & Noda, M. (2010) · Journal of Oral Biosciences · doi:10.1016/s1349-0079(10)80011-8
Buschke-Ollendorf Syndrome: Report of a Case and a Brief Molecular Overview
van Geel, M., Verstraeten, V. L. R. M., Lucker, G. P. H., & Steensel, M. A. M. V. (2008) · The Open Dermatology Journal · doi:10.2174/1874372200802010005
“For example, sclerosteosis (OMIM 269500) is caused by loss of fucntion of the SOST gene coding for the BMP antagonist sclerostin [12].”
Metadata
- Authors
- Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P., & Mulligan, J. T.
- Affiliations
- University of Cape Town (ZA)
- University of Cagliari (IT)
- Corresponding author
- Brunkow, Mary E.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 68
- Issue
- 3
- Pages
- 577-589
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1274471
- OpenAlex
- W2037750372
- Cited by
- 1,011
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 32 · 2023: 27 · 2022: 36 · 2021: 53 · 2020: 52 · 2019: 46 · 2018: 50 · 2017: 56 · 2016: 65 · 2015: 61 · 2014: 58 · 2013: 60 · 2012: 56
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4523 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- sclerosteosis, SOST gene, skeletal dysplasia, cystine knot proteins, bone homeostasis, skeletal overgrowth, nonsense mutation, splicing mutation, founder effect, Afrikaner population, bone formation regulation
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Bone Diseases, Chromosome Mapping, Chromosomes, Human, Pair 17, Consanguinity, Cystine, Female, Genetic Markers, Homozygote, Humans, Male, Molecular Sequence Data, Netherlands, Pedigree, Proteins, Recombination, Genetic, Sclerosis, Senegal, South Africa, Conserved Sequence, Alternative Splicing, Bone Morphogenetic Proteins, Mutation, Missense, Black People, White People, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.